source
- Agios’ second shot at sickle cell disease falls shortAgios said it is dropping a next-generation sickle cell disease drug after lackluster results from a mid-stage trial. The drug, known as tebapivat, represented Agios’ second shot at the disease, an…Endpoints · 8d ago↗ source
- Notes from a peptide meetupWith an FDA advisory committee set to decide this week whether it recommends that several popular peptides be reclassified, I wanted to learn more. Cue a last-minute ticket purchase to ...Endpoints · 8d ago↗ source
- STAT+: Advocates say federal funding is being cut from groups fighting HIVThe administration is shifting some funding to states, but community groups are set to lose out.STAT · 8d ago↗ source